Identification of tissue biomarkers related to late toxicity in Head and Neck Cancer Patients treated with chemoradiotherapy or bioradiotherapy

Trial Profile

Identification of tissue biomarkers related to late toxicity in Head and Neck Cancer Patients treated with chemoradiotherapy or bioradiotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms BioLateTox
  • Most Recent Events

    • 08 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top